Rautenberg, Tamlyn A.
Ng, Shu Kay
George, Gavin
Moosa, Mahomed-Yunus S.
McCluskey, Suzanne M.
Gilbert, Rebecca F.
Pillay, Selvan
Aturinda, Isaac
Ard, Kevin L.
Muyindike, Winnie R.
Musinguzi, Nicholas
Masette, Godfrey
Pillay, Melendhran
Moodley, Pravi
Brijkumar, Jaysingh
Gandhi, Rajesh T.
Johnson, Brent
Sunpath, Henry
Bwana, Mwebesa B.
Marconi, Vincent C.
Siedner, Mark J.
Funding for this research was provided by:
National Institutes of Health (NIH R01 AI124718)
Article History
Received: 18 January 2023
Accepted: 2 August 2023
First Online: 21 August 2023
Declarations
:
: The trial was approved by the institutional review committees at the Mbarara University of Science and Technology, the Uganda National Council for Science and Technology, the University of KwaZulu-Natal, Mass General Brigham and Griffith University. All participants provided signed informed consent.
: Not applicable.
: VCM has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV. RG received support from the Harvard University Center for AIDS Research (NIH P30 AI060354) and the AIDS Clinical Trials Group (NIH/NIAID 2 UMAI069412-09). SM reports grants from National Institutes of Health, grants from Gilead Sciences, grants from ViiV Healthcare, grants from Massachusetts General Hospital, personal fees from US Centers for Disease Control (through Potentia Namibia Recruitment), outside the submitted work. There are no other financial or non-financial competing interests to declare.